intravascular injection used contrast medium colloidal suspension chronic exposure especially organs reticuloendothelial german thorotrast study comprises NUMBER thorotrast patients NUMBER contemporary matched patients control group evaluated NUMBER thorotrast patients NUMBER controls clinical biophysical examinations years NUMBER recent important results study high excess rate primary liver cancer observed beginning 15th year exposure NUMBER tumors combined cirrhosis NUMBER neoplastic diseases clear mean dose rate effect relationship exists tumor frequency depends time exposure cumulative dose liver respectively primarily age injection lowest cumulative doses NUMBER years diagnosis liver cancer NUMBER gy risk estimates liver cancer NUMBER years exposure NUMBER malignant tumors NUMBER men NUMBER women high excess rate exists leukaemias excluding cll starting NUMBER years thorotrast injection lowest cumulative doses red bone marrow time death NUMBER gy according present result excess rate expected carcinomas extrahepatic bile ducts pancreas oesophagus larynx lymphomas bone sarcomas plasmacytomas mesotheliomas thorotrast thorium dioxide causes alpha particles follow person gy non hodgkins NUMBER NUMBER NUMBER NUMBER